Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Dermatology

The Road to Remission: Modern Treatment Standards

At a Glance

Modern pemphigus vulgaris (PV) treatment relies on a two-phase approach using fast-acting corticosteroids to stop blister formation, followed by rituximab to deplete the B-cells causing the disease. This strategy aims for complete remission while allowing doctors to safely lower steroid doses.

The approach to treating Pemphigus Vulgaris (PV) has undergone a dramatic transformation in recent years. While the disease was once managed with years of high-dose steroids, modern guidelines now favor a “fast and targeted” approach that aims for deep remission while protecting your body from the long-term side effects of medication.

The Modern First-Line Strategy

Current international guidelines (such as those from the EADV and AAD) now recognize Rituximab as a first-line therapy for moderate-to-severe PV [1][2].

The standard treatment “road map” typically follows two phases:

  1. Rapid Control: You will likely start on systemic corticosteroids (like Prednisone). These act like a fire extinguisher, quickly dampening the inflammation and stopping new blisters from forming [3].
  2. Disease Modification: Shortly after starting steroids, you will receive Rituximab. While steroids treat the symptoms, Rituximab treats the source by depleting the B-cells that produce the harmful autoantibodies [4][5].

What to Expect: The Rituximab Infusion

Rituximab is a biologic “monoclonal antibody.” In PV, it is typically given as two intravenous infusions, spaced 14 days apart [6][7].

  • The Infusion: You will receive the medication in a clinic or hospital setting. The infusion typically takes several hours.
  • Pre-medications: To prevent infusion reactions, you will usually be given premedications such as Tylenol (acetaminophen), Benadryl (diphenhydramine), and sometimes a dose of IV steroids [7]. You may feel very sleepy during and after the infusion.
  • The Timeline: Rituximab does not work overnight. It can take several weeks to months to reach its full effect and clear the existing antibodies from your blood; patience is key during this transition [1].

The primary benefit of Rituximab is its steroid-sparing effect [1]. Because it is so effective at inducing remission, it allows your doctor to taper (slowly reduce) your prednisone dose much faster than was possible in the past [3][4].

The Brutal Reality of Corticosteroid Risks

While steroids are necessary to save your skin and mouth in the short term, high-dose systemic corticosteroids have severe, immediate side effects that patients must prepare for:

  • Physical and Mental Impact: You may experience intense mood swings, profound insomnia, significant weight gain, and facial swelling (“moon facies”) [8][9].
  • Long-Term Risks: Prolonged use can lead to high blood sugar (steroid-induced diabetes), osteoporosis (bone thinning), and cataracts [8].
  • Coping: Ask your doctor about strategies to manage these side effects, such as taking your dose early in the morning to help with sleep, and working with a dietitian. Tapering off steroids safely is a major priority.

Critical Safety Warning: Infection Risks

Every powerful immunosuppressant involves a “trade-off.” Because Rituximab depletes your B-cells and high-dose steroids suppress your immune system, you are at a significantly higher risk for serious infections [5]. Infections are a leading cause of complications in treated PV patients [10].

  • Vaccinations: You must complete any necessary non-live vaccines (like the flu, COVID-19, or pneumococcal vaccines) before starting Rituximab [11].
  • Prophylaxis: Your doctor may prescribe prophylactic antibiotics (like Bactrim) to prevent specific opportunistic infections, such as Pneumocystis pneumonia (PCP) [10].
  • Vigilance: Any fever, even a low-grade one, should be treated as a medical emergency. Do not ignore signs of illness.

The Role of Other Therapies

  • Adjuvant Immunosuppressants: Medications like Azathioprine or Mycophenolate Mofetil may be used if Rituximab is not an option [12][5].
  • IVIG (Intravenous Immunoglobulin): This is often used as a “rescue therapy” for very severe or refractory cases [13][14].

With modern protocols, the prognosis for PV is excellent. Most patients can achieve complete remission, and many are eventually able to stop all medications entirely [5][6].

Next: Learn how to assemble the experts you need in Building Your Care Team.

Common questions in this guide

Is rituximab considered a first-line treatment for pemphigus vulgaris?
Yes, current international guidelines recognize rituximab as a first-line therapy for moderate-to-severe pemphigus vulgaris. It treats the source of the disease by depleting the B-cells that produce harmful autoantibodies.
Why do I need to take prednisone at the same time as rituximab?
Prednisone and other systemic corticosteroids act like a fire extinguisher to rapidly stop inflammation and prevent new blisters. Because rituximab can take weeks or months to reach its full effect, steroids bridge the gap to provide immediate symptom relief.
What are the side effects of high-dose steroids for pemphigus?
High-dose systemic corticosteroids can cause severe side effects, including intense mood swings, insomnia, profound weight gain, and facial swelling. Prolonged use increases the risk of high blood sugar, osteoporosis, and cataracts.
Why do I need vaccines before starting rituximab?
Rituximab depletes your B-cells and significantly suppresses your immune system, putting you at a much higher risk for serious infections. You must complete any necessary non-live vaccines before treatment to ensure your body has optimal protection.
What is IVIG and when is it used for pemphigus vulgaris?
Intravenous Immunoglobulin (IVIG) is typically used as a rescue therapy for very severe or refractory cases of pemphigus vulgaris. It is considered when first-line treatments like rituximab and corticosteroids do not achieve remission.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given the severity of my condition, is Rituximab being considered as a first-line treatment for me?
  2. 2.What is your specific timeline and protocol for tapering my prednisone once the Rituximab begins to take effect?
  3. 3.How will we monitor my risk for infections while I am on B-cell depleting therapy, and should I take prophylactic antibiotics?
  4. 4.Am I a candidate for 'rescue' therapies like IVIG if my initial treatment doesn't achieve remission?
  5. 5.What vaccinations do I need to complete before I start my first Rituximab infusion?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Consensus on the treatment of autoimmune bullous dermatoses: pemphigus vulgaris and pemphigus foliaceus - Brazilian Society of Dermatology.

    Porro AM, Hans Filho G, Santi CG

    Anais brasileiros de dermatologia 2019; (94(2 Suppl 1)):20-32 doi:10.1590/abd1806-4841.2019940206.

    PMID: 31166407
  2. 2

    Pemphigus Vulgaris: Clinical Aspects and Treatments.

    Geng RSQ, Sibbald RG

    Advances in skin & wound care 2025; (38(5)):232-238 doi:10.1097/ASW.0000000000000307.

    PMID: 40184525
  3. 3

    A 10-Year Observational Study on Treatment Approaches in Pemphigus and Pemphigoid.

    Pereira CP, Santos R, Ferreira L, et al.

    Acta stomatologica Croatica 2025; (59(2)):190-198 doi:10.15644/asc59/2/8.

    PMID: 40641586
  4. 4

    A retrospective cohort study reporting rituximab treatment for 33 patients with immunobullous disease.

    Watson N, Carrozzo M, Hampton P

    Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2021; (50(1)):92-97 doi:10.1111/jop.13123.

    PMID: 33184901
  5. 5

    Rituximab versus Mycophenolate Mofetil in Patients with Pemphigus Vulgaris.

    Werth VP, Joly P, Mimouni D, et al.

    The New England journal of medicine 2021; (384(24)):2295-2305 doi:10.1056/NEJMoa2028564.

    PMID: 34097368
  6. 6

    Pemphigus Vulgaris: Present and Future Therapeutic Strategies.

    Didona D, Paolino G, Di Zenzo G, et al.

    Dermatology practical & conceptual 2022; (12(1)):e2022037 doi:10.5826/dpc.1201a37.

    PMID: 35223181
  7. 7

    A Comparative Study to Evaluate the Efficacy and Cost of Rituximab versus Dexamethasone Cyclophosphamide Pulse in Patients of Pemphigus Vulgaris.

    Das S, Agarwal K, Singh S, et al.

    Indian journal of dermatology 2021; (66(2)):223 doi:10.4103/ijd.IJD_306_20.

    PMID: 34188295
  8. 8

    Management of pemphigus vulgaris: challenges and solutions.

    Gregoriou S, Efthymiou O, Stefanaki C, Rigopoulos D

    Clinical, cosmetic and investigational dermatology 2015; (8()):521-7 doi:10.2147/CCID.S75908.

    PMID: 26543381
  9. 9

    Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.

    Chen DM, Odueyungbo A, Csinady E, et al.

    The British journal of dermatology 2020; (182(5)):1111-1119 doi:10.1111/bjd.18482.

    PMID: 31487383
  10. 10

    A Case Report of Pemphigus Vulgaris Initially Misdiagnosed as Tinea Capitis: Infectious Consequences of Diagnostic Delay in a Patient Treated With Rituximab.

    González-Rodríguez JC, Cristofori M, Antunez Oliva JA, Cortés-Marín EE

    Cureus 2025; (17(7)):e87662 doi:10.7759/cureus.87662.

    PMID: 40673286
  11. 11

    Rituximab as a maintenance treatment in patients with pemphigus vulgaris: When is the right time for discontinuation?

    Aryanian Z, Balighi K, Emadi SN, Hatami P

    Journal of cosmetic dermatology 2024; (23(2)):406-408 doi:10.1111/jocd.16030.

    PMID: 37916650
  12. 12

    Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and single-centre long-term review of nine patients.

    Robinson AJ, Vu M, Unglik GA, et al.

    The Australasian journal of dermatology 2018; (59(1)):e47-e52 doi:10.1111/ajd.12571.

    PMID: 28211049
  13. 13

    Long-Term Remissions in Recalcitrant Pemphigus Vulgaris.

    Ahmed AR, Kaveri S, Spigelman Z

    The New England journal of medicine 2015; (373(27)):2693-4 doi:10.1056/NEJMc1508234.

    PMID: 26716930
  14. 14

    Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.

    Grando SA

    International journal of dermatology 2019; (58(1)):114-125 doi:10.1111/ijd.14143.

    PMID: 30047585

This page explains modern pemphigus vulgaris treatments for educational purposes only. Always consult your dermatologist or care team before making changes to your immunosuppressive medications or steroid taper plan.

Get notified when new evidence is published on Pemphigus vulgaris.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.